291 related articles for article (PubMed ID: 16506635)
1. Management of xerostomia related to radiotherapy for head and neck cancer.
Kahn ST; Johnstone PA
Oncology (Williston Park); 2005 Dec; 19(14):1827-32; discussion 1832-4, 1837-9. PubMed ID: 16506635
[TBL] [Abstract][Full Text] [Related]
2. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
[TBL] [Abstract][Full Text] [Related]
3. Current therapies for xerostomia and salivary gland hypofunction associated with cancer therapies.
Nieuw Amerongen AV; Veerman EC
Support Care Cancer; 2003 Apr; 11(4):226-31. PubMed ID: 12673460
[TBL] [Abstract][Full Text] [Related]
4. New approaches to preventing xerostomia.
J Support Oncol; 2006 Feb; 4(2):87-8. PubMed ID: 16499130
[No Abstract] [Full Text] [Related]
5. [Current status of prevention and management of radiation-induced xerostomia].
Ma DY; Qiu WL; Zhang CP
Zhonghua Kou Qiang Yi Xue Za Zhi; 2010 Feb; 45(2):121-3. PubMed ID: 20368009
[No Abstract] [Full Text] [Related]
6. Pathophysiology and management of radiation-induced xerostomia.
Berk LB; Shivnani AT; Small W
J Support Oncol; 2005; 3(3):191-200. PubMed ID: 15915820
[TBL] [Abstract][Full Text] [Related]
7. Radiation-induced xerostomia: how dry is your patient?
Bruce SD
Clin J Oncol Nurs; 2004 Feb; 8(1):61-7. PubMed ID: 14983765
[TBL] [Abstract][Full Text] [Related]
8. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
Thorstad WL; Chao KS; Haughey B
Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes of submandibular gland transfer for prevention of postradiation xerostomia.
Seikaly H; Jha N; Harris JR; Barnaby P; Liu R; Williams D; McGaw T; Rieger J; Wolfaardt J; Hanson J
Arch Otolaryngol Head Neck Surg; 2004 Aug; 130(8):956-61. PubMed ID: 15313866
[TBL] [Abstract][Full Text] [Related]
10. Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients.
de Castro G; Federico MH
Curr Opin Oncol; 2006 May; 18(3):266-70. PubMed ID: 16552239
[TBL] [Abstract][Full Text] [Related]
11. Management of salivary hypofunction during and after radiotherapy.
Shiboski CH; Hodgson TA; Ship JA; Schiødt M
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Mar; 103 Suppl():S66.e1-19. PubMed ID: 17379158
[TBL] [Abstract][Full Text] [Related]
12. Radiation-induced xerostomia.
Chambers MS; Rosenthal DI; Weber RS
Head Neck; 2007 Jan; 29(1):58-63. PubMed ID: 16906511
[TBL] [Abstract][Full Text] [Related]
13. Phase III randomized study: oral pilocarpine versus submandibular salivary gland transfer protocol for the management of radiation-induced xerostomia.
Jha N; Seikaly H; Harris J; Williams D; Sultanem K; Hier M; Ghosh S; Black M; Butler J; Sutherland D; Kerr P; Barnaby P
Head Neck; 2009 Feb; 31(2):234-43. PubMed ID: 19107948
[TBL] [Abstract][Full Text] [Related]
14. Pilocarpine in the prevention of postirradiation xerostomia.
Lajtman Z; Krajina Z; Krpan D; Vincelj J; Borcić V; Popović-Kovacić J
Acta Med Croatica; 2000; 54(2):65-7. PubMed ID: 11028111
[TBL] [Abstract][Full Text] [Related]
15. Preventing radiation induced xerostomia.
Koukourakis MI; Danielidis V
Cancer Treat Rev; 2005 Nov; 31(7):546-54. PubMed ID: 16257125
[TBL] [Abstract][Full Text] [Related]
16. Functional outcomes related to the prevention of radiation-induced xerostomia: oral pilocarpine versus submandibular salivary gland transfer.
Rieger JM; Jha N; Lam Tang JA; Harris J; Seikaly H
Head Neck; 2012 Feb; 34(2):168-74. PubMed ID: 21416547
[TBL] [Abstract][Full Text] [Related]
17. A randomized study to assess the effectiveness of orally administered pilocarpine during and after radiotherapy of head and neck cancer.
Nyárády Z; Németh A; Bán A; Mukics A; Nyárády J; Ember I; Olasz L
Anticancer Res; 2006; 26(2B):1557-62. PubMed ID: 16619571
[TBL] [Abstract][Full Text] [Related]
18. Amifostine reduces radiation therapy-induced dry mouth in head and neck cancer patients.
Oncology (Williston Park); 2004 Sep; 18(10):1314, 1316. PubMed ID: 15526835
[No Abstract] [Full Text] [Related]
19. Oral complications of cancer therapies. Management of salivary dysfunction.
Greenspan D
NCI Monogr; 1990; (9):159-61. PubMed ID: 2342589
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of cevimeline to improve oral health in patients with postradiation xerostomia.
Witsell DL; Stinnett S; Chambers MS
Head Neck; 2012 Aug; 34(8):1136-42. PubMed ID: 22231734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
